|1.||Moyer, Mary Pat: 4 articles (04/2012 - 01/2011)|
|2.||Liu, Zhihua: 4 articles (04/2012 - 01/2011)|
|3.||Qin, Huanlong: 4 articles (04/2012 - 01/2011)|
|4.||Zhang, Peng: 3 articles (04/2012 - 01/2011)|
|5.||Ma, Yanlei: 3 articles (04/2012 - 01/2011)|
|6.||Shen, Tongyi: 2 articles (01/2011 - 01/2011)|
|7.||Signorelli, Kathy L: 2 articles (08/2006 - 08/2003)|
|8.||Hadden, John W: 2 articles (08/2003 - 05/2002)|
|9.||Shi, Chenzhang: 1 article (04/2012)|
|10.||Chen, Hongqi: 1 article (01/2011)|
01/01/2011 - "To further analyze the protective effects conferred to intestinal epithelial cells by MIMP, we established transient MIMP-expressing NCM460 cells (NCM460/MIMP) as a means of assessing their susceptibility to infection. "
01/01/2011 - "Fluorescence further showed that NCM460/MIMP cells had significantly higher TJ protein staining intensity ocompared to NCM460 cells and transmission electron microscopy indicated that TJ structure was unchanged in NCM460/MIMP cells infected with EPEC compared to NCM460 cells after EPEC infection. "
01/01/2011 - "Expression of the Lactobacillus plantarum surface layer MIMP protein protected NCM460 epithelial cells from enteroinvasive Escherichia coli infection."
08/01/2006 - "3, 1205-1215), there were no improvements in the outcomes of infection in the inbred animals treated with MIMP intranasally 1 day before the challenge and/or orally after the challenge for 5 days (up to 10 mg/kg/day). "
05/01/2002 - "Intravenous (i.v.) administration of MIMP 1 day prior to influenza virus infection could confer partial protection and significantly increase the mean survival of treated mice. "
|2.||Communicable Diseases (Infectious Diseases)
|3.||Human Influenza (Influenza)
05/01/2002 - "Complete survival and reduction of viral load after influenza challenge infection suggests effective stimulation by MIMP of protective responses against influenza virus."
05/01/2002 - "Intranasal (i.n.) administration of MIMP improved survival rates and incorporation of MIMP in squalane-saline emulsion 1 day prior to or 1 h after influenza infection conferred complete protection. "
08/01/2006 - "An inbred murine model (BALB/c) was utilized to assess the protective effect of the immunomodulator methyl inosine 5'-monophosphate (MIMP) against infection with influenza A/PR/8/34 (H1N1) virus. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
09/01/1995 - "MIMP also augments the PHA responses of eight HIV-infected pre-AIDS patients but not of eight AIDS patients. "
05/01/1992 - "MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression."
05/01/1992 - "In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. "
|5.||HIV Infections (HIV Infection)
|2.||methyl inosine monophosphate (MIMP)
|3.||Toll-Like Receptor 5
|4.||p38 Mitogen-Activated Protein Kinases
|5.||Cytochromes c (Cytochrome c)
|6.||Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
|9.||Influenza Vaccines (FluMist)